Toggle menu

NOVEL Study

Start date:
May/June 2018
Co-ordinated by:
LumiraDx
Main trial site:
Royal Infirmary Edinburgh

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Primary Objective: evaluation of diagnostic platform with biomarkers useful in emergency settings.

Sample: Patients over 18 years old presenting to the Emergency Department with mainly symptoms of cardiovascular conditions.

Trial Design: Prospective observational (cohort) feasibility study

Chief Investigator

Professor Alasdair Gray

Director of EMERGE & Consultant in Emergency Medicine

Research Team

Adam Lloyd

PhD Student & Senior Research Nurse

Alison Grant

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Polly Black

Senior Research Nurse

Mia Paderanga

Senior Research Nurse

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA

Identification of Novel Psychoactive Substances (IONA)

Patients commonly present to the Emergency Department with epistaxsis (nose bleed). Standard first aid measures such as applying pressure can often stem bleeding however in more severe cases of epistaxsis further treatment is required.

Read more

NoPac

Novel Use of Tranexamic Acid to Reduce the Need for Nasal Packing